Omega-6 fatty acids
While some complementary and alternative techniques have been studied scientifically, high-quality data regarding safety, effectiveness, and mechanism of action are limited or controversial for most therapies. Whenever possible, it is recommended that practitioners be licensed by a recognized professional organization that adheres to clearly published standards. In addition, before starting a new technique or engaging a practitioner, it is recommended that patients speak with their primary healthcare provider(s). Potential benefits, risks (including financial costs), and alternatives should be carefully considered. The below monograph is designed to provide historical background and an overview of clinically-oriented research, and neither advocates for or against the use of a particular therapy.
- Omega-6 fatty acids are a family of polyunsaturated fatty acids including linoleic acid, gamma-linolenic acid, and arachidonic acid. In North America, omega-6 fatty acids are found in adequate amounts in the diet, as they are found in salad dressings, margarines, and other plant and animal oil sources. The negative reputation of omega-6 fatty acids is likely based on inadequate intakes of omega-3 fatty acids and not excessive omega-6 fatty acid intakes.
- Although not commonly used alone as dietary supplements, there is some evidence in support of omega-6 fatty acids, in combination with omega-3 fatty acids, for attention-deficit hyperactivity disorder (ADHD) and coordination disorders, as well as eye disorders. Also, levels of certain omega-6 fatty acids in the blood were found to be lower in multiple sclerosis patients vs. healthy controls with similar dietary intakes. However, there is a lack of evidence in support of supplementation in multiple sclerosis patients.
These uses have been tested in humans or animals. Safety and effectiveness have not always been proven. Some of these conditions are potentially serious, and should be evaluated by a qualified healthcare provider.
|C||ADHD (attention-deficit hyperactivity disorder)
Both omega-3 (mainly docosahexaenoic acid) and omega-6 (mainly gamma-linolenic acid) fatty acids have been studied in patients with ADHD. Further research is needed before conclusions may be drawn.
Both omega-3 (mainly docosahexaenoic acid) and omega-6 (mainly gamma-linolenic acid) fatty acids have been studied in patients with developmental disorders and ADHD. Further research is needed.
|C||Eye disorders (meibomian gland dysfunction)
Limited research suggests that a supplement containing omega-6 fatty acids may improve the symptoms of meibomian gland dysfunction. However, it is not clear if the supplement also contained other agents. Additional research on the use of omega-6 fatty acids alone is needed before conclusions may be drawn.
|C||Healing after photorefractive keratectomy
Limited research suggests that a supplement containing omega-6 fatty acids may improve the results of photorefractive keratectomy (a type of laser eye surgery). However, it is not clear if the supplement also contained other agents. Additional research on the use of omega-6 fatty acids alone is needed before conclusions may be drawn.
Lower levels of certain omega-6 fatty acids were detected in the plasma of multiple sclerosis patients than in healthy controls. Additional research is required before conclusions may be drawn.
*Key to grades:
The below uses are based on tradition or scientific theories. They often have not been thoroughly tested in humans, and safety and effectiveness have not always been proven. Some of these conditions are potentially serious and should be evaluated by a qualified health care professional.
- Arthritis, atopic dermatitis, cancer, cystic fibrosis, depression, diabetes, heart disease, high cholesterol, HIV/AIDS, immune system regulation, inflammation, liver damage (from impaired bile flow), mastalgia (breast pain), neurological disorders.
The below doses are based on scientific research, publications, traditional use, or expert opinion. Many herbs and supplements have not been thoroughly tested, and safety and effectiveness may not be proven. Brands may be made differently, with variable ingredients, even within the same brand. The below doses may not apply to all products. You should read product labels, and discuss doses with a qualified healthcare provider before starting therapy.
Adults (18 years and older)
- For eye disorders (meibomian gland dysfunction), 28.5 milligrams of linoleic acid and 15 milligrams of gamma-linolenic acid have been taken by mouth daily for 180 days in Medilar™ tablets (a combination product), which also contain omega-3 fatty acids, vitamin E, vitamin C, vitamin B6, vitamin B12, and zinc.
- For multiple sclerosis, 11-23 grams of linoleic acid has been taken by mouth daily. Information on the duration of treatment was lacking.
Children (under 18 years old)
- There is no proven safe or effective dose of omega-6 fatty acids in children.
The U.S. Food and Drug Administration does not strictly regulate herbs and supplements. There is no guarantee of strength, purity or safety of products, and effects may vary. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy. Consult a healthcare provider immediately if you experience side effects.
- Avoid with known allergy or hypersensitivity to potential vegetable oil sources of omega-6 fatty acids, such as corn oil, sunflower oil, and soybean oil.
- It is commonly thought that the increase in omega-6 fatty acids in the diet in North America plays a role in the increased prevalence of allergies.
Side Effects and Warnings
- Omega-6 fatty acids are considered to be safe and healthy fatty acids and are commonly found in the diet. However, many health experts believe that, based on the high omega-6 fatty acid intakes in North America, it may be important to increase omega-3 fatty acids in the diet, thus reducing the omega-6:omega-3 fatty acid intake ratio.
- Omega-6 fatty acids may have procancer effects or harmful effects on the heart. They may also be associated with Crohn’s disease, excessive fat tissue development, attention-deficit hyperactivity disorder (ADHD), depression, neuroticism, altered depression scale scores, development of parenteral nutrition-associated liver disease in children with short bowel syndrome, an elevated risk of fracture in the elderly, Reye’s syndrome, exercise-induced asthma, or a high rejection rate in kidney transplants.
- Omega-6 fatty acids may increase the risk of bleeding. Caution is advised in patients with bleeding disorders or those taking drugs, herbs, or supplements that may increase the risk of bleeding. Dosing adjustments may be necessary.
- Omega-6 fatty acids may cause insulin resistance and affect blood sugar levels. Caution is advised in patients with diabetes or low blood sugar and in those taking drugs, herbs, or supplements that affect blood sugar. Blood glucose levels may need to be monitored by a qualified healthcare professional, including a pharmacist. Medication adjustments may be necessary.
- Omega-6 fatty acids may cause high blood pressure. Caution is advised in patients taking drugs, herbs, or supplements that lower blood pressure.
- Caution is advised when used in combination with anti-inflammatory agents, as omega-6 fatty acids are considered proinflammatory as a group.
- Caution is advised when used in patients with heart disease, those prone to cancer or taking anticancer agents, those prone to bone fracture or taking medications for osteoporosis, those with psychiatric disorders or taking psychiatric medications, and those using cholesterol-lowering agents.
- Avoid supplementation with arachidonic acid, based on theoretical increases in inflammation and disorders caused by inflammatory processes, including heart disease.
- Avoid with known allergy or hypersensitivity to potential vegetable oil sources of omega-6 fatty acids, such as corn oil, sunflower oil, and soybean oil. It is commonly thought that the increase in omega-6 fatty acids in the diet in North America plays a role in the increased prevalence of allergies.
Pregnancy and Breastfeeding
- There is a lack of high-quality scientific evidence on the use of omega-6 supplements in pregnant or breastfeeding women. In early research, compared with women giving birth to full-term infants, arachidonic acid and all omega-6 fatty acids were higher in women giving birth to preterm infants.
Most herbs and supplements have not been thoroughly tested for interactions with other herbs, supplements, drugs, or foods. The interactions listed below are based on reports in scientific publications, laboratory experiments, or traditional use. You should always read product labels. If you have a medical condition, or are taking other drugs, herbs, or supplements, you should speak with a qualified healthcare provider before starting a new therapy.
Interactions with Drugs
- Omega-6 fatty acids may cause insulin resistance and affect blood sugar levels. Caution is advised when using medications that may also affect blood sugar. Patients taking insulin or drugs for diabetes by mouth should be monitored closely by a qualified healthcare professional, including a pharmacist. Medication adjustments may be necessary.
- Omega-6 fatty acids may increase the risk of bleeding when taken with drugs that increase the risk of bleeding. Some examples include aspirin, anticoagulants (blood thinners) such as warfarin (Coumadin®) or heparin, antiplatelet drugs such as clopidogrel (Plavix®), and nonsteroidal anti-inflammatory drugs such as ibuprofen (Motrin®, Advil®) or naproxen (Naprosyn®, Aleve®).
- Omega-6 fatty acids may cause high blood pressure. Caution is advised in patients taking drugs that lower blood pressure.
- Omega-6 fatty acids may also interact with agents that affect the immune system, agents used for the heart, antiasthmatics, anticancer agents, anti-inflammatory agents, cholesterol-lowering agents, clofibric acid, drugs used for osteoporosis, estrogen and progestin combinations, gentamicin, iron, neurologic agents, norepinephrine, psychiatric agents, or thyroid hormones.
Interactions with Herbs and Dietary Supplements
- Omega-6 fatty acids may cause insulin resistance and affect blood sugar levels. Caution is advised when using herbs or supplements that may also lower blood sugar. Blood glucose levels may require monitoring, and doses may need adjustment.
- Omega-6 fatty acids may increase the risk of bleeding when taken with herbs and supplements that are believed to increase the risk of bleeding. Multiple cases of bleeding have been reported with the use of Ginkgo biloba, and fewer cases with garlic and saw palmetto. Numerous other agents may theoretically increase the risk of bleeding, although this has not been proven in most cases.
- Omega-6 fatty acids may cause high blood pressure. Caution is advised in patients taking herbs or supplements that lower blood pressure.
- Omega-6 fatty acids may also interact with alpha-linolenic acid supplements, alpha-linolenic acid-containing foods, antiasthmatics, anticancer agents, anti-inflammatories, beef fat, beta-carotene, cholesterol-lowering agents, docosahexaenoic acid, fish, flaxseed, flaxseed oil, formula diets, herbs and supplements used for the heart, herbs and supplements that affect the immune system, iron, a Mediterranean diet, neurological agents, omega-3 fatty acids, osteoporosis herbs and supplements, psychiatric agents, quercetin, saturated fat, tetradecylthioacetic acid, trans fat, vitamin A, vitamin E, or a Western-type diet.
- This information is based on a systematic review of scientific literature edited and peer-reviewed by contributors to the Natural Standard Research Collaboration (www.naturalstandard.com).
Natural Standard developed the above evidence-based information based on a thorough systematic review of the available scientific articles. For comprehensive information about alternative and complementary therapies on the professional level, go to www.naturalstandard.com. Selected references are listed below.
- Ailhaud G. Omega-6 fatty acids and excessive adipose tissue development. World Rev Nutr Diet 2008;98:51-61. View Abstract
- An WS, Kim SE, Kim KH, et al. Comparison of fatty acid contents of erythrocyte membrane in hemodialysis and peritoneal dialysis patients. J Ren Nutr 2009;19(4):267-274. View Abstract
- Aupperle RL, Denney DR, Lynch SG, et al. Omega-3 fatty acids and multiple sclerosis: relationship to depression. J Behav Med 2008;31(2):127-135. View Abstract
- Colter AL, Cutler C, Meckling KA. Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents: a case-control study. Nutr J 2008;7:8. View Abstract
- Diamond IR, Sterescu A, Pencharz PB, et al. The rationale for the use of parenteral omega-3 lipids in children with short bowel syndrome and liver disease. Pediatr Surg Int 2008;24(7):773-778. View Abstract
- Harris WS, Mozaffarian D, Rimm E, et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 2009;119(6):902-907. View Abstract
- Johnson M, Ostlund S, Fransson G, et al. Omega-3/omega-6 fatty acids for attention deficit hyperactivity disorder: a randomized placebo-controlled trial in children and adolescents. J Atten Disord 2009;12(5):394-401. View Abstract
- Kilari AS, Mehendale SS, Dangat KD, et al. Long chain polyunsaturated fatty acids in mothers and term babies. J Perinat Med 2009;37(5):513-518. View Abstract
- Querques G, Russo V, Barone A, et al. Efficacy of omega-6 essential fatty acid treatment before and after photorefractive keratectomy. J Fr Ophtalmol 2008;31(3):282-286. View Abstract
- Rashid S, Jin Y, Ecoiffier T, et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol 2008;126(2):219-225. View Abstract
- Raz R, Gabis L. Essential fatty acids and attention-deficit-hyperactivity disorder: a systematic review. Dev Med Child Neurol 2009;51(8):580-592. View Abstract
- Seti H, Leikin-Frenkel A, Werner H. Effects of omega-3 and omega-6 fatty acids on IGF-I receptor signalling in colorectal cancer cells. Arch Physiol Biochem 2009;115(3):127-136. View Abstract
- Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med (Maywood) 2008;233(6):674-688. View Abstract
- Tanaka T, Shen J, Abecasis GR, et al. Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study. PLoS Genet 2009;5(1):e1000338. View Abstract
- Tribole, E. What happened to do no harm? The issue of dietary omega-6 fatty acids. Prostaglandins Leukot Essent Fatty Acids 2009;80(1):78-79. View Abstract
Copyright © 2013 Natural Standard (www.naturalstandard.com)
The information in this monograph is intended for informational purposes only, and is meant to help users better understand health concerns. Information is based on review of scientific research data, historical practice patterns, and clinical experience. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions.